Efgartigimod alfa (subcutaneous injection) for treating generalised myasthenia gravis

Efgartigimod alfa is currently in clinical development for the treatment of adults with generalised myasthenia gravis (gMG). gMG is a rare, long-term autoimmune disorder that leads to muscle weakness and tiredness, which can be seriously debilitating and life-threatening, affecting eye alignment, swallowing, speech, mobility and respiratory function. These symptoms can significantly impair independence and quality of life. Currently, there are few treatment options for gMG, and medicines that can take a long time to work and result in side-effects, which can limit their use.